Mayne Pharma has acquired the rights to the fentanyl transdermal delivery system (TDS), from Par Pharmaceutical Inc. The product was developed by Corium, a specialty pharma company focused on the development and manufacture of transdermal and transmucosal delivery systems. 

Fentanyl TDS is a generic equivalent to Duragesic, indicated for severe pain management in opioid-tolerant patients requiring daily treatment. Mayne Pharma has assumed Par’s manufacturing and supply agreement with Corium, and acquired select inventory and the rights to market the product. According to IMS Health, annual market sales for the fentanyl patch were approximately $560 million in 2016. 

Mayne Pharma’s chief executive officer Scott Richards said, “We are very pleased to have partnered with Corium on another complex and difficult-to-develop and manufacture product. The U.S. transdermal patch market is valued at more than $3.3 billion and is a well-regarded advanced drug delivery system that can better control drug release and can also lead to improved patient convenience and compliance. Our alliance with Corium now includes two marketed and one pipeline product that is currently filed with the U.S. FDA, and reinforces one of the key strategic benefits of the Teva portfolio acquisition to access a pipeline of new product opportunities through leveraging relationships with active pharmaceutical ingredient suppliers and contract development and manufacturing companies.”